Emerging pharmaceutical company, ANI Pharmaceuticals Inc. (NASDAQ:ANIP), recently announced the extension of a fee for service product development agreement with Sterling Pharmaceutical Services. The generic drug product that will form basis of the agreement has not yet been disclosed. ANI Pharmaceuticals Inc (NASDAQ:ANIP) shares after opening at $24.89 moved to $25.73 on last trade day and at the end of the day closed at $25.55. Company price to sales ratio in past twelve months was calculated as 9.57 and price to cash ratio as 25.96. ANI Pharmaceuticals Inc (NASDAQ:ANIP) showed a negative weekly performance of -4.24%.
OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlight OncoMed’s drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares advanced 3.96% in last trading session and ended the day on $25.99. OMED return on equity ratio is recorded as 20.27% and its return on assets is 2.42%.
Corcept Therapeutics Incorporated (NASDAQ:CORT) slumped -6.85%, the company in recent past entered into a manufacturing agreement with AAIPharma Services Corp. (AAI), pursuant to which AAI will manufacture and package Korlym tablets. We will supply mifepristone, the active pharmaceutical ingredient in Korlym, to AAI for use in the manufacture of the product. AAI will manufacture the product in accordance with FDA and other regulatory requirements. Corcept Therapeutics Incorporated (NASDAQ:CORT) shares moved up 5.80% in last trading session and was closed at $3.83, while trading in range of $ 3.55 – 3.87. Corcept Therapeutics Incorporated (NASDAQ:CORT) year to date (YTD) performance is 19.31%.
Pfizer Inc. (NYSE:PFE) has also sued several other drugmakers, including Mylan and Actavis, which are also seeking FDA approval to market generic versions of Celebrex. Analysts say similar mutually beneficial settlements with these firms could be forthcoming in the near future. Pfizer Inc. (NYSE:PFE) weekly performance is -1.18%. On last trading day company shares ended up $30.25. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -4.42%. Analysts mean target price for the company is $34.15.
Leave a Reply